[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369636-105":59,"doc-detail-369636-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","multicenter-study-correlating-molecular-characteristics-and-clinical-outcomes-of-cancer-cases-with-patient-derived-organoids","Multicenter study correlating molecular characteristics and clinical outcomes of cancer cases with patient-derived organoids","","This multicenter prospective study evaluates whether patient-derived organoids (PDOs) can be established from diverse patient samples and timepoints, and whether PDO molecular features and drug sensitivity track clinical outcomes. Data from three multicenter cohorts included 184 patients covering 17 tumor types and 249 collected samples from tumor tissue, peritoneal fluids, and peripheral blood. PDOs reproduced pathological and immunohistochemical patterns, confirmed pathogenic variants in 84%, and in sequential baseline-to-treatment PDO series mirrored patient therapeutic responses, supporting PDOs as complementary precision-medicine models.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multicenter-study-correlating-molecular-characteristics-and-clinical-outcomes-of-cancer-cases-with-patient-derived-organoids/369636/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multicenter-study-correlating-molecular-characteristics-and-clinical-outcomes-of-cancer-cases-with-patient-derived-organoids/369636.png","ImageObject",300,407,{"name":92,"@type":93},"Rizky","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the multicenter study?","Question",{"text":112,"@type":113},"To determine whether patient-derived organoids (PDOs) can be established from different biological samples and timepoints, and whether their characteristics and drug sensitivity correlate with clinical outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many patients and samples were analyzed?",{"text":117,"@type":113},"The study included 184 patients across 17 tumor types and collected 249 samples, drawn from tumor tissue, peritoneal fluids, and peripheral blood.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence shows PDOs reflect patient responses to therapy?",{"text":121,"@type":113},"In a series of baseline and sequential PDOs from treated patients, therapy response patterns in PDOs mirrored the corresponding patient responses during treatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369636,1790232761,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Navarro et al. J Exp Clin Cancer Res (2025) 44:182 [https://doi.org/10.1186/s13046-025-03437-0](https://doi.org/10.1186/s13046-025-03437-0)  \nJournal of Experimental & Clinical Cancer Research  \n RESEARCH Open Access  \nMulticenter study correlating molecular  \ncharacteristics and clinical outcomes of cancer cases with patient-derived organoids  \nPaloma Navarro 1,2,3,4†, Tatiana P. Grazioso 1,2,3,4†, Arantzazu Barquín 1,2,3,4, Maria Barba 1,3, Mónica Yagüe1,3, Carlos Millán3,5, Irene López3,5, Elena Sevillano1,2,3,4, Miguel Quiralte1,2,3,4, Paloma Fernández4, Diego Losada 1,2,3, Eduardo Caleiras6, Julia Calzas8, Beatriz Jiménez3,7,8, Sergio Ruiz‑Llorente 1,4,9, Juan Justo2,10,11, Félix Guerrero12, Vital Hevia 12, Raquel Martín 13, Francisco José Pérez‑Rodriguez 13, Julia Tejerina14, Mario Prieto 13,  \nPaula Comune15, Juan Francisco Rodriguez‑Moreno1,2,3,4 and Jesús García‑Donás1,2,3,4*  \nAbstract  \nBackground 3D‑spatial interaction between cancer cells influences tumor behavior, making it essential to replicate tumor structures for predicting patient outcomes.  \nMethods We collected data from three multicenter prospective studies to evaluate the ability to establish Patient‑ Derived Organoids (PDOs) from different biological samples and timepoints, correlating their characteristics and drug sensitivity with clinical outcomes.  \nResults From 184 patients (17 tumor types), 249 samples were collected: 149 (59 . 8%) from tumor tissue, 61 (24 . 5%) from peritoneal fluids, 39 (15 . 7%) from peripheral blood. Success rates for PDO establishment were 39 . 5%, 34 .4%, and 25. 6%, respectively. PDOs reproduced pathological and immunohistochemical patterns of source tumors, with pathogenic variants confirmed in 84%(21/25) . In a series of 13 baseline and sequential PDOs from 9 patients undergoing treatment, responses to therapy mirrored patient responses during therapy.  \nConclusions PDOs preserve tumor features, reflect disease progression, and predict treatment responses, providing valuable models to complement molecular testing in precision medicine.  \nKeywords Precision Medicine, Patient‑derived organoids, Drug screening  \nBackground  \nCancer is the leading cause of death in the world. According to the World Health Organization (WHO), about 10 million people died from this entity in 2020, and about 19 million people were newly diagnosed [1].  \n†Paloma Navarro and Tatiana P. Grazioso contributed equally to this work.  \n*Correspondence:  \nJesús García‑Donás  \n[jgarciadonas@hmhospitales.com](jgarciadonas@hmhospitales.com)  \nFull list of author information is available at the end of the article  \nDespite significant advances in the management of this disease, only a minority of patients benefit from genetic testing and precision medicine today [2, 3]. On one hand, most medications already approved for cancer have overlapping clinical indications, while on the other hand, many mechanisms of resistance are driven by adaptations in the epigenetic profiles of tumors or their microenvironment, which cannot be properly assessed by current molecular assays [4–7]. Consequently, determining the best therapeutic option for each case remains a difficult decision that both physicians and patients must face daily.  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permis","cbCaitCw2PR8kpGh","https://ap.wps.com/l/cbCaitCw2PR8kpGh","pdf",6037403,24,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background\n## Rationale for PDO-based models\n# Authors and Publication Info","[{\"question\":\"What is the main goal of the multicenter study?\",\"answer\":\"To determine whether patient-derived organoids (PDOs) can be established from different biological samples and timepoints, and whether their characteristics and drug sensitivity correlate with clinical outcomes.\"},{\"question\":\"How many patients and samples were analyzed?\",\"answer\":\"The study included 184 patients across 17 tumor types and collected 249 samples, drawn from tumor tissue, peritoneal fluids, and peripheral blood.\"},{\"question\":\"What evidence shows PDOs reflect patient responses to therapy?\",\"answer\":\"In a series of baseline and sequential PDOs from treated patients, therapy response patterns in PDOs mirrored the corresponding patient responses during treatment.\"}]","Multicenter study correlating molecular characteristics and clinical outcomes of cancer cases with patient-derived organoids | PDF",1790183774,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c237b6c05a6e8b656827883e8a9f989.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/646b77a7952b47add5d492c8a94a10ec.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee764196ae65a41bf4983fe27b7963b3.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64bfc0c8f557a6c270b075b61815b060.webp",980,1301]